<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="131073">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01839877</url>
  </required_header>
  <id_info>
    <org_study_id>FFCD 1201 DEBIRI</org_study_id>
    <nct_id>NCT01839877</nct_id>
  </id_info>
  <brief_title>Intra-arterial Hepatic Beads Loaded With Irinotecan With Concomitant Chemotherapy With FOLFOX in Patients With Colorectal Cancer With Unresectable Liver Metastases: a Phase II Multicenter Study</brief_title>
  <official_title>Intra-arterial Hepatic Beads Loaded With Irinotecan With Concomitant Chemotherapy With FOLFOX in Patients With Colorectal Cancer With Unresectable Liver Metastases: a Phase II Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federation Francophone de Cancerologie Digestive</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biocompatibles UK Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Federation Francophone de Cancerologie Digestive</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment of patients with colorectal cancer having liver metastases is currently based on
      systemic chemotherapy.

      Triple therapy with 5FU, oxaliplatin and irinotecan intravenously was effective in terms of
      response and secondary resectability, however it is particularly toxic.

      Hepatic intra-arterial chemotherapy (HIA) has been the subject of several studies. It has
      shown good efficacy with oxaliplatin and FUDR. However, the procedure is difficult to set up
      and reserved for experienced centers.

      The objective of this protocol is to use a triple therapy based on 5FU and oxaliplatin
      associated to irinotecan which is administered by hepatic intra-arterial route, loaded onto
      microbeads (DEBIRI). Furthermore, the procedure for chemo-embolization DEBIRI is limited to
      2 sessions, and therefore could be more easily generalized.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progression-free survival rate at 9 months</measure>
    <time_frame>at 9 months after inclusion</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety of the study treatment</measure>
    <time_frame>at 9 months after inclusion</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adverse event rate; all grade, grades 1-2 and grades 3-4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years after last patient in</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Colorectal Cancer With Non Resectable Hepatic Metastasis</condition>
  <arm_group>
    <arm_group_label>HIA DEBIRI + systemic FOLFOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intra-arterial hepatic beads loaded with irinotecan with systemic FOLFOX</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HIA DEBIRI + systemic FOLFOX</intervention_name>
    <arm_group_label>HIA DEBIRI + systemic FOLFOX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven colorectal adenocarcinoma,

          -  Liver metastases radiologically or histologically proven

          -  At least one measurable liver lesions by RECIST v1.1

          -  Age ≥ 18 years

          -  WHO Index &lt; or = 2

          -  Life expectancy ≥ 3 months

          -  No extrahepatic disease except lung nodules if number &lt; or = 3 and size &lt; 10 mm each

          -  Healthy liver &lt;60%

          -  Primary tumor resected or still in place

          -  No prior chemotherapy for metastases treatment (except a perioperative chemotherapy,
             if the last cycle was administered at least 12 months ago)

          -  Adjuvant chemotherapy after resection of the primary authorized if the last cycle was
             administered at least 12 months ago

          -  Normal hepatic function: total bilirubin ≤ 1.5 N; AST ≤ 5N; ALT ≤ 5N and PAL ≤ 5N

          -  TP ≥ 60%

          -  Adequate hematologic function: ANC ≥ 1500/mm3, platelets ≥ 100 000/mm3, Hb ≥ 9g/dl

          -  Good renal function: creatinine clearance ≥ 60 mL / min

          -  No cardiac dysfunction: no cardiovascular events in the last 6 months or no NYHA ≥ 2

        Exclusion Criteria:

          -  Patient eligible for curative treatment (resection and / or radiofrequency ablation)
             by a multidisciplinary decision (including the opinion of a liver surgeon)

          -  Pregnant or lactating woman or patients of both sexes and of childbearing age not
             using adequate contraception

          -  History of cancer, except skin cancer (other than melanoma), carcinoma in situ of the
             cervix uteri treated curative. Other cancers treated with curative intent are
             permitted provided they did not relapse over the last 5 years

          -  Peripheral neuropathy

          -  Inflammatory Bowel Diseases

          -  Intestinal obstruction

          -  Chronic liver disease (viral, alcoholic or metabolic)

          -  Immune Deficiency Syndromes (history of transplantation, infection with HIV)

          -  Known to have contraindications to 5FU, oxaliplatin, folinic acid, irinotecan or to
             contrast products

          -  Patients with known contraindications against hepatic embolization procedures:

        Presence of biliary-digestive anastomosis or biliary stent Cruoric or tumor thrombosis of
        the portal vein

          -  Patient who for psychological, social, family or geographical reasons could not be
             followed up regularly

          -  Legal disability (persons deprived of liberty or under guardianship)

          -  Patient is not affiliated to a social security scheme

          -  Participation in another concurrent study investigating the effect of treatment and
             this until 4 weeks after the end of the concurrent study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julien TAIEB, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fédération Francophone de Cancérologie Digestive</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julien TAIEB, Pr</last_name>
    <phone>33 1 56 09 50 42</phone>
    <email>julien.taieb@egp.aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Simon PERNOT, Dr</last_name>
    <phone>33 1 56 09 50 42</phone>
    <email>simon.pernot@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hopital Saint André</name>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denis SMITH, Dr</last_name>
      <phone>33 5 56 79 58 08</phone>
      <email>denis.smith@chu-bordeaux.fr</email>
    </contact>
    <contact_backup>
      <last_name>Thibault CARTERET, Dr</last_name>
      <phone>33 5 56 79 58 00</phone>
      <email>thibault.carteret@chu-bordeaux.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hôpital Prive Jean Mermoz</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascal ARTRU, Pr</last_name>
      <phone>33 4 78 74 08 64</phone>
      <email>dr.artru@wanadoo.fr</email>
    </contact>
    <contact_backup>
      <last_name>Jérome DESRAME, Dr</last_name>
      <phone>33 37 53 87 26</phone>
      <email>jerome.desrame@orange.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centre Léon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christelle DE LA FOUCHARDIERE, Pr</last_name>
      <phone>33 4 78 78 51 36</phone>
      <email>christelle.delafouchardiere@lyon.unicancer.fr</email>
    </contact>
    <contact_backup>
      <last_name>Franck PILLEUL, Dr</last_name>
      <phone>33 4 78 78 51 36</phone>
      <email>frank.pilleul@lyon.unicancer.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHU de la TIMONE</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laetitia DAHAN, Dr</last_name>
      <phone>33 4 91 38 82 13</phone>
      <email>laetitia.dahan@ap-hm.fr</email>
    </contact>
    <contact_backup>
      <last_name>Vincent VIDAL, Dr</last_name>
      <phone>33 4 91 38 56 69</phone>
      <email>vincent.vidal@ap-hm.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmette</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Luc RAOUL, Pr</last_name>
      <phone>33 4 99 25 31 96</phone>
      <email>raouljl@ipc.unicancer.fr</email>
    </contact>
    <contact_backup>
      <last_name>Anthony SARRAN, Dr</last_name>
      <phone>33 4 91 22 34 13</phone>
      <email>sarrana@marseille.fnclcc.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hôpital Europeen G Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien TAIEB</last_name>
      <phone>33 1 56 09 50 42</phone>
      <email>julien.taieb@egp.aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Simon PERNOT</last_name>
      <phone>33 1 56 09 50 42</phone>
      <email>simon.pernot@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Pitie-Salpetriere</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier DUBREUIL, Dr</last_name>
      <phone>33 1 42 16 10 41</phone>
      <email>olivier.dubreuil@psl.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Milétrie</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurélie FERRU, Dr</last_name>
      <phone>33 5 49 44 48 71</phone>
      <email>a.ferru@chu-poitiers.fr</email>
    </contact>
    <contact_backup>
      <last_name>Jean-Pierre TASU, Dr</last_name>
      <phone>33 5 49 44 44 32</phone>
      <email>j.p.tasu@chu-poitiers.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHU Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pïerre MICHEL, Pr</last_name>
      <phone>33 2 32 88 64 56</phone>
      <email>pierre.michel@chu-rouen.fr</email>
    </contact>
    <contact_backup>
      <last_name>Frédéric DI Fiore, Dr</last_name>
      <phone>33 2 32 88 86 10</phone>
      <email>Frederic.Di-Fiore@chu-rouen.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hôpital Rangueil</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosine GUIMBAUD, Pr</last_name>
      <phone>33 5 61 32 21 42</phone>
      <email>guimbaud.r@chu-toulouse.fr</email>
    </contact>
    <contact_backup>
      <last_name>Philippe OTAL, Dr</last_name>
      <phone>33 5 61 32 28 51</phone>
      <email>otal.p@chu-toulouse.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>March 3, 2014</lastchanged_date>
  <firstreceived_date>April 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic colorectal Cancer</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
